Drugs / TmPSMA-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05489991 | Sep 2022 → May 2023 | prostate carcinoma | Tceleron Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TmPSMA-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05489991 ↗ |
| Modality | Cell therapy | “genetically modified autologous T-cells” NCT05489991 ↗ |
| Route | Intravenous | “will be infused intravenously” NCT05489991 ↗ |